Your session is about to expire
← Back to Search
Xenon MRI for Pulmonary Arterial Hypertension (Jupiter PH Trial)
Jupiter PH Trial Summary
This trial is studying how disease progression and treatment affects changes in gas exchange and blood flow in people with pulmonary arterial hypertension.
Jupiter PH Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowJupiter PH Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Jupiter PH Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have sickle cell anemia.I am between 18 and 75 years old.You have any health conditions that make it impossible to have a 129Xe MRI scan.My liver condition is severe.I have been diagnosed with sarcoidosis.My pulmonary hypertension is caused by schistosomiasis.I have moderate to severe heart disease.My cancer is currently active.I can undergo an MRI scan without issues.My pulmonary hypertension symptoms are moderate.I have not started treatment or started it within the last 3 months.I have been diagnosed with a specific type of high blood pressure in my lungs.I am on the waiting list for a lung transplant.
- Group 1: end-stage pulmonary hypertension .
- Group 2: following pulmonary arterial hypertension subjects
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this experiment actively seeking out participants?
"The data being hosted on clinicaltrials.gov reveals this medical experiment is actively enrolling patients, with its first posting dating back to September 1st 2021 and the most recent change occurring on November 15th 2022."
What detrimental effects might patients experience from using this treatment?
"Based on the Phase 2 trial data available, Power has determined that this treatment can be considered a moderate risk with a score of 2."
Is my eligibility sufficient to join this medical study?
"For this clinical trial, 60 individuals suffering from pulmonary arterial hypertension and aged between 18 to 75 are being admitted. Specific enrolment criteria include: outpatients of either gender; prerequisite for lung transplantation; PAH diagnosis as demonstrated by right heart catheterization (mPAP ≥25 mmHg, PVR≥3 WU, PCWP ≤15mmHg); willingness to provide informed consent and comply with the protocol schedule; women that have not yet entered menopause must pass a urine pregnancy test before MRI."
Does this medical trial accept individuals below fifty years old as participants?
"This medical research is seeking volunteers aged 18 and above, yet below 75 years of age."
What is the overall participant tally for this clinical experiment?
"Correct. According to the data on clinicaltrials.gov, this medical trial is actively recruiting patients who meet its criteria. The study was initially posted on September 1st 2021 and has since been updated in November 15th 2022 with a total of 60 participants required from one location."
Share this study with friends
Copy Link
Messenger